BMS Prepares To Move Opdivo Into Neoadjuvant Lung Cancer

 
• By Joseph Haas

BMS reports event-free survival advantage, adding to earlier findings that Opdivo plus chemotherapy met statistical significance for pathologic complete response in the CheckMate-816 study.

Lung Cancer
BMS is looking to move into earlier lines of NSCLC therapy with Opdivo

More from Immuno-oncology

More from Anticancer